Rui Fei (瑞菲)瑞菲
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 江苏恒瑞医药股份有限公司Chinese legal name: 江苏恒瑞医药股份有限公司
主要成分Active Ingredients
- 非索非那定Feisuo Feina Ding
药物知识说明
非索非那定是一种在国家药监局注册认定的药品。该药品含有非索非那定-ce781638等成分。
该药品关联的活性成分包括：非索非那定Feisuo Feina Ding。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：江苏恒瑞医药股份有限公司Chinese legal name: 江苏恒瑞医药股份有限公司。
您可以探索含有相同成分的其他药品：非索非那定-ce781638成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 瑞菲) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 非索非那定Feisuo Feina Ding.
Manufacturers recorded for this product: 江苏恒瑞医药股份有限公司Chinese legal name: 江苏恒瑞医药股份有限公司.
Explore other medicines containing the same ingredient: 非索非那定 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 瑞菲Recorded Chinese name: 瑞菲
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 60mg*12片60 mg × 12 tablets
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 江苏恒瑞医药股份有限公司Chinese legal name: 江苏恒瑞医药股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20040901
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20040901
Manufacturer
Chinese legal name: 江苏恒瑞医药股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Keep sealed.
Specification
60 mg × 12 tablets
中文说明书原文Original Chinese source label
批准文号
国药准字H20040901
生产企业
江苏恒瑞医药股份有限公司(国产)
适应症
本品适用于减轻季节性过敏性鼻炎和慢性特发性荨麻疹引起的症状。
用法用量
成人、12岁及12岁以上的儿童:口服，一日一次，一次120mg。肾功能不全的患者推荐起始剂量为60mg，一日一次。
不良反应
在对照性临床研究中，最常报道的非索非那定的不良反应是头痛、嗜睡、恶心、头昏、疲倦。这些不良反应与安慰剂组观察到的相似。其中嗜睡和疲倦发生率为1.3%，恶心和消化不良发生率为1.6%，头痛和白细胞增多发生率为1.5%。目前尚未见到有关非索非那定引起严重心脏毒性的报道。
禁忌
对本品过敏者禁用。
注意事项
肝功能不全者不需减量，肾功能不全的患者剂量需减半。
贮藏
密封。
规格
60mg*12片
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.